相关实验视频
Updated: Jul 10, 2025

07:37
An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
Published on: June 6, 2025
136
在类风湿性关节炎中准IL-6或IL-6受体:我们学到了什么?
Ali Berkant Avci1, Eugen Feist2, Gerd R Burmester3
1Department of Internal Medicine, Rheumatology, Medical Park Antalya Hospital, Antalya, Türkiye.
概括
干白素-6 (IL-6) 抑制有效治疗类风湿性关节炎. 新的研究探索了直接IL-6阻断和IL-6受体阻断剂,为个性化治疗策略提供了希望.
科学领域:
- 免疫学 免疫学 免疫学
- 类风湿病学 类风湿病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 干白素-6 (IL-6) 在类风湿性关节炎的发病过程中起着至关重要的作用.
- 抑制IL-6已经成为一种有价值的治疗策略,改善了治疗耐药患者的治疗结果.
- IL-6通路抑制剂的开发扩大了类风湿性关节炎的治疗选择.
研究的目的:
- 审查目前的IL-6抑制在类风湿性关节炎治疗中的情况.
- 讨论不同IL-6向剂的安全性和有效性,包括IL-6受体阻断剂和直接IL-6抑制剂.
- 探索个性化医疗方法在风湿性关节炎管理中的未来方向和潜力.
主要方法:
- 审查现有的临床试验数据和关于IL-6抑制剂的科学文献.
- 对托西利祖马布,沙利卢马布,奥洛基祖马布和西鲁库马布的安全性和疗效概况的分析.
- 检查IL-6受体阻塞和直接IL-6抑制之间的机制差异.
主要成果:
- 像托西利祖马布和沙利祖马布这样的IL-6受体抑制剂在类风湿性关节炎中显示出显著的疗效和安全性.
- 针对不同IL-6区域的Olokizumab显示出有前途的安全性和有效性,缓解了早期药物试验带来的担忧.
- 生物类似药和新型强效IL-6受体阻断剂的开发正在加速.
结论:
- 抑制IL-6是现代风湿性关节炎治疗的基石,提供有效的治疗选择.
- 了解IL-6通路抑制的细微差别对于优化个性化治疗策略至关重要.
- 需要进一步的长期临床数据和基础研究来完善针对个体患者的IL-6向机制的选择.
相关概念视频
The JAK-STAT Signaling Pathway
8.9K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.9K
T Cell Types and Functions
1.0K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.0K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
146
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
146
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
168
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
168

